{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:45:31Z","timestamp":1794606331688,"version":"4.9.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Guangxi Natural Science Foundation","award":["2025JJH140422"],"award-info":[{"award-number":["2025JJH140422"]}]},{"name":"the Key Research Program of Guangxi Science and Technology Department","award":["AB21196010"],"award-info":[{"award-number":["AB21196010"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82560016, 82104499, and 82160783"],"award-info":[{"award-number":["82560016, 82104499, and 82160783"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Health and Family Planning Commission of Guangxi Zhuang Autonomous Region, Self-funded Projects","award":["Z-A20240492 and Z-A20240515"],"award-info":[{"award-number":["Z-A20240492 and Z-A20240515"]}]},{"name":"Joint Project on Regional High-Incidence Diseases Research of Guangxi Natural Science Foundation","award":["2023GXNSFBA026146"],"award-info":[{"award-number":["2023GXNSFBA026146"]}]},{"name":"First-class Discipline Innovation-driven Talent Program of Guangxi Medical University, and the Health and Family Planning Commission of Guangxi Zhuang Autonomous Region","award":["S2025124"],"award-info":[{"award-number":["S2025124"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-026-04257-4","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T05:17:01Z","timestamp":1777007821000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Inhaled tobramycin for chronic pseudomonas aeruginosa infection in non-cystic fibrosis bronchiectasis: an updated systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Wei","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiujie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaochu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinliang","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"4257_CR1","doi-asserted-by":"publisher","unstructured":"Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, Murris M, Cant\u00f3n R, Torres A, Dimakou K et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629. https:\/\/doi.org\/10.1183\/13993003.00629-2017.","DOI":"10.1183\/13993003.00629-2017"},{"key":"4257_CR2","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2147\/COPD.S6133","volume":"4","author":"PT King","year":"2009","unstructured":"King PT. The pathophysiology of bronchiectasis. Int J Chronic Obstr Pulm Dis. 2009;4:411\u20139.","journal-title":"Int J Chronic Obstr Pulm Dis"},{"key":"4257_CR3","doi-asserted-by":"publisher","unstructured":"Amati F, Simonetta E, Gramegna A, Tarsia P, Contarini M, Blasi F, Aliberti S. The biology of pulmonary exacerbations in bronchiectasis. Eur respiratory review: official J Eur Respiratory Soc. 2019;28(154):190055. https:\/\/doi.org\/10.1183\/16000617.0055-2019.","DOI":"10.1183\/16000617.0055-2019"},{"issue":"11","key":"4257_CR4","first-page":"Cd008351","volume":"2015","author":"AL Lee","year":"2015","unstructured":"Lee AL, Burge AT, Holland AE. Airway clearance techniques for bronchiectasis. Cochrane Database Syst Rev. 2015;2015(11):Cd008351.","journal-title":"Cochrane Database Syst Rev"},{"key":"4257_CR5","doi-asserted-by":"publisher","unstructured":"Guan WJ, Han XR, de la Rosa-Carrillo D, Martinez-Garcia MA. The significant global economic burden of bronchiectasis: a pending matter. Eur Respir J. 2019;53(2):1802392. https:\/\/doi.org\/10.1183\/13993003.02392-2018.","DOI":"10.1183\/13993003.02392-2018"},{"issue":"7","key":"4257_CR6","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S2213-2600(23)00136-4","volume":"11","author":"SH Chotirmall","year":"2023","unstructured":"Chotirmall SH, Dhar R, McShane PJ, Chang AB. Bronchiectasis: a global disease necessitating global solutions. Lancet Respiratory Med. 2023;11(7):581\u20133.","journal-title":"Lancet Respiratory Med"},{"key":"4257_CR7","doi-asserted-by":"crossref","unstructured":"Keir HR, Chalmers JD. Pathophysiology of Bronchiectasis. Seminars in respiratory and critical care medicine. 2021;42(4):499\u2013512.","DOI":"10.1055\/s-0041-1730891"},{"key":"4257_CR8","doi-asserted-by":"publisher","unstructured":"Chalmers JD, Metersky M, Aliberti S, Morgan L, Fucile S, Lauterio M, McDonald PP. Neutrophilic inflammation in bronchiectasis. Eur respiratory review: official J Eur Respiratory Soc. 2025;34(176):240179. https:\/\/doi.org\/10.1183\/16000617.0179-2024.","DOI":"10.1183\/16000617.0179-2024"},{"issue":"2","key":"4257_CR9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ccm.2012.02.004","volume":"33","author":"BC Moulton","year":"2012","unstructured":"Moulton BC, Barker AF. Pathogenesis of bronchiectasis. Clin Chest Med. 2012;33(2):211\u20137.","journal-title":"Clin Chest Med"},{"key":"4257_CR10","doi-asserted-by":"publisher","unstructured":"Ara\u00fajo D, Shteinberg M, Aliberti S, Goeminne PC, Hill AT, Fardon TC, Obradovic D, Stone G, Trautmann M, Davis A et al. The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis. Eur Respir J. 2018;51(2):1701953. https:\/\/doi.org\/10.1183\/13993003.01953-2017.","DOI":"10.1183\/13993003.01953-2017"},{"issue":"1","key":"4257_CR11","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1080\/07853890.2021.1900594","volume":"53","author":"R Wang","year":"2021","unstructured":"Wang R, Ding S, Lei C, Yang D, Luo H. The contribution of Pseudomonas aeruginosa infection to clinical outcomes in bronchiectasis: a prospective cohort study. Ann Med. 2021;53(1):459\u201369.","journal-title":"Ann Med"},{"issue":"11","key":"4257_CR12","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1513\/AnnalsATS.201506-333OC","volume":"12","author":"S Finch","year":"2015","unstructured":"Finch S, McDonnell MJ, Abo-Leyah H, Aliberti S, Chalmers JD. A Comprehensive Analysis of the Impact of Pseudomonas aeruginosa Colonization on Prognosis in Adult Bronchiectasis. Annals Am Thorac Soc. 2015;12(11):1602\u201311.","journal-title":"Annals Am Thorac Soc"},{"issue":"8","key":"4257_CR13","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1164\/rccm.202501-0159OC","volume":"211","author":"RC Hull","year":"2025","unstructured":"Hull RC, Stobo J, Abo-Leyah H, Richardson H, Alferes de Lima Headley D, Long MB, Hennayake C, Gilmour A, Johnson ED, Tunney M, et al. Endotypes of Pseudomonas aeruginosa Infection in Bronchiectasis Are Associated with Inhaled Antibiotic Response: Results from Two Randomized, Double-Blind, Placebo-controlled Phase III Trials (ORBIT 3 and ORBIT 4). Am J Respir Crit Care Med. 2025;211(8):1397\u2013408.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"4257_CR14","doi-asserted-by":"publisher","first-page":"ofz546","DOI":"10.1093\/ofid\/ofz546","volume":"7","author":"DM Jacobs","year":"2020","unstructured":"Jacobs DM, Ochs-Balcom HM, Noyes K, Zhao J, Leung WY, Pu CY, Murphy TF, Sethi S. Impact of Pseudomonas aeruginosa Isolation on Mortality and Outcomes in an Outpatient Chronic Obstructive Pulmonary Disease Cohort. Open forum Infect Dis. 2020;7(1):ofz546.","journal-title":"Open forum Infect Dis"},{"issue":"3","key":"4257_CR15","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cmi.2019.07.010","volume":"26","author":"YH Chai","year":"2020","unstructured":"Chai YH, Xu JF. How does Pseudomonas aeruginosa affect the progression of bronchiectasis? Clin Microbiol infection: official publication Eur Soc Clin Microbiol Infect Dis. 2020;26(3):313\u20138.","journal-title":"Clin Microbiol infection: official publication Eur Soc Clin Microbiol Infect Dis"},{"issue":"6","key":"4257_CR16","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1378\/chest.114.6.1594","volume":"114","author":"PL Ho","year":"1998","unstructured":"Ho PL, Chan KN, Ip MS, Lam WK, Ho CS, Yuen KY, Tsang KW. The effect of Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis. Chest. 1998;114(6):1594\u20138.","journal-title":"Chest"},{"key":"4257_CR17","doi-asserted-by":"publisher","unstructured":"Song J, Sin S, Kang HR, Oh YM, Jeong I. Clinical Impacts of Pseudomonas aeruginosa Isolation in Patients with Bronchiectasis: Findings from KMBARC Registry. J Clin Med. 2024;13(17):5011. https:\/\/doi.org\/10.3390\/jcm13175011.","DOI":"10.3390\/jcm13175011"},{"key":"4257_CR18","doi-asserted-by":"publisher","unstructured":"Pieters A, Bakker M, Hoek RAS, Altenburg J, van Westreenen M, Aerts J, van der Eerden MM. The clinical impact of Pseudomonas aeruginosa eradication in bronchiectasis in a Dutch referral centre. Eur Respir J. 2019;53(4):1802081. https:\/\/doi.org\/10.1183\/13993003.02081-2018.","DOI":"10.1183\/13993003.02081-2018"},{"issue":"1","key":"4257_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.chest.2024.01.045","volume":"166","author":"R Cordeiro","year":"2024","unstructured":"Cordeiro R, Choi H, Haworth CS, Chalmers JD. The Efficacy and Safety of Inhaled Antibiotics for the Treatment of Bronchiectasis in Adults: Updated Systematic Review and Meta-Analysis. Chest. 2024;166(1):61\u201380.","journal-title":"Chest"},{"issue":"10","key":"4257_CR20","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S2213-2600(19)30185-7","volume":"7","author":"IF Laska","year":"2019","unstructured":"Laska IF, Crichton ML, Shoemark A, Chalmers JD. The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis. Lancet Respiratory Med. 2019;7(10):855\u201369.","journal-title":"Lancet Respiratory Med"},{"key":"4257_CR21","doi-asserted-by":"crossref","unstructured":"Evans DJ, Greenstone M. Long-term antibiotics in the management of non-CF bronchiectasis\u2013do they improve outcome? Respiratory medicine. 2003;97(7):851\u20138.","DOI":"10.1016\/S0954-6111(03)00063-5"},{"issue":"2","key":"4257_CR22","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1183\/09031936.00018414","volume":"44","author":"AM Brodt","year":"2014","unstructured":"Brodt AM, Stovold E, Zhang L. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review. Eur Respir J. 2014;44(2):382\u201393.","journal-title":"Eur Respir J"},{"issue":"7","key":"4257_CR23","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1164\/rccm.201203-0487OC","volume":"186","author":"JD Chalmers","year":"2012","unstructured":"Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2012;186(7):657\u201365.","journal-title":"Am J Respir Crit Care Med"},{"key":"4257_CR24","doi-asserted-by":"publisher","first-page":"106728","DOI":"10.1016\/j.rmed.2021.106728","volume":"192","author":"JS Elborn","year":"2022","unstructured":"Elborn JS, Blasi F, Haworth CS, Ballmann M, Tiddens H, Murris-Espin M, Chalmers JD, Cantin AM. Bronchiectasis and inhaled tobramycin: A literature review. Respir Med. 2022;192:106728.","journal-title":"Respir Med"},{"issue":"5","key":"4257_CR25","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1080\/17476348.2022.2057951","volume":"16","author":"SB Fiel","year":"2022","unstructured":"Fiel SB, Roesch EA. The use of tobramycin for Pseudomonas aeruginosa: a review. Expert Rev Respir Med. 2022;16(5):503\u20139.","journal-title":"Expert Rev Respir Med"},{"issue":"1","key":"4257_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJM199901073400104","volume":"340","author":"BW Ramsey","year":"1999","unstructured":"Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev KM, Borowitz D, Bowman CM, Marshall BC, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999;340(1):23\u201330.","journal-title":"N Engl J Med"},{"issue":"2 Pt 1","key":"4257_CR27","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1164\/ajrccm.162.2.9910086","volume":"162","author":"AF Barker","year":"2000","unstructured":"Barker AF, Couch L, Fiel SB, Gotfried MH, Ilowite J, Meyer KC, O\u2019Donnell A, Sahn SA, Smith LJ, Stewart JO, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med. 2000;162(2 Pt 1):481\u20135.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"4257_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1345\/aph.1E099","volume":"39","author":"ME Drobnic","year":"2005","unstructured":"Drobnic ME, Su\u00f1\u00e9 P, Montoro JB, Ferrer A, Orriols R. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Annals pharmacotherapy. 2005;39(1):39\u201344.","journal-title":"Annals pharmacotherapy"},{"issue":"1","key":"4257_CR29","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.chest.2022.07.007","volume":"163","author":"WJ Guan","year":"2023","unstructured":"Guan WJ, Xu JF, Luo H, Xu XX, Song YL, Ma WL, Liang ZA, Liu XD, Zhang GJ, Zhang XJ, et al. A Double-Blind Randomized Placebo-Controlled Phase 3 Trial of Tobramycin Inhalation Solution in Adults With Bronchiectasis With Pseudomonas aeruginosa Infection. Chest. 2023;163(1):64\u201376.","journal-title":"Chest"},{"key":"4257_CR30","doi-asserted-by":"publisher","first-page":"108136","DOI":"10.1016\/j.rmed.2025.108136","volume":"243","author":"Z Zhong","year":"2025","unstructured":"Zhong Z, Zhang C, Zhao L, Zhao Y, Xia S. Inhaled tobramycin in non-cystic fibrosis bronchiectasis: A meta-analysis of randomized controlled trials. Respir Med. 2025;243:108136.","journal-title":"Respir Med"},{"key":"4257_CR31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2174\/1874306401509010030","volume":"9","author":"M Vendrell","year":"2015","unstructured":"Vendrell M, Mu\u00f1oz G, de Gracia J. Evidence of inhaled tobramycin in non-cystic fibrosis bronchiectasis. open respiratory Med J. 2015;9:30\u20136.","journal-title":"open respiratory Med J"},{"key":"4257_CR32","doi-asserted-by":"publisher","first-page":"106283","DOI":"10.1016\/j.rmed.2020.106283","volume":"176","author":"S Sangiovanni","year":"2021","unstructured":"Sangiovanni S, Morales EI, Fern\u00e1ndez-Trujillo L. Inhaled tobramycin for chronic infection with pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis: A systematic review and meta-analysis. Respir Med. 2021;176:106283.","journal-title":"Respir Med"},{"issue":"1","key":"4257_CR33","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1186\/s12931-022-02243-y","volume":"23","author":"LC Terpstra","year":"2022","unstructured":"Terpstra LC, Altenburg J, Bronsveld I, de Kruif MD, Berk Y, Snijders D, Rozemeijer W, Heijerman HGM, Boersma WG. Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis. Respir Res. 2022;23(1):330.","journal-title":"Respir Res"},{"issue":"5","key":"4257_CR34","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1089\/jamp.2020.1606","volume":"34","author":"E Tanriverdi","year":"2021","unstructured":"Tanriverdi E, Yildirim BZ, Gul S, Chousein EGU, Turan D, \u00c7\u0131narka H, \u00d6zg\u00fcl MA, Cetinkaya E. Results of Tobramycin Inhalation Therapy in Patients with Noncystic Fibrosis Bronchiectasis with Pseudomonas aeruginosa Colonization: Real Life Management. J aerosol Med pulmonary drug delivery. 2021;34(5):274\u20139.","journal-title":"J aerosol Med pulmonary drug delivery"},{"key":"4257_CR35","first-page":"n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical Res ed). 2021;372:n71.","journal-title":"BMJ (Clinical Res ed)"},{"key":"4257_CR36","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jclinepi.2021.02.003","volume":"134","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Moher D. Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol. 2021;134:103\u201312.","journal-title":"J Clin Epidemiol"},{"key":"4257_CR37","doi-asserted-by":"publisher","unstructured":"Hill AT, Haworth CS, Aliberti S, Barker A, Blasi F, Boersma W, Chalmers JD, De Soyza A, Dimakou K, Elborn JS et al. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur Respir J. 2017;49(6):1700051. https:\/\/doi.org\/10.1183\/13993003.00051-2017.","DOI":"10.1183\/13993003.00051-2017"},{"key":"4257_CR38","first-page":"l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clinical Res ed. 2019;366:l4898.","journal-title":"BMJ (Clinical Res ed"},{"issue":"2","key":"4257_CR39","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","volume":"56","author":"S Duval","year":"2000","unstructured":"Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455\u201363.","journal-title":"Biometrics"},{"issue":"7650","key":"4257_CR40","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical Res ed). 2008;336(7650):924\u20136.","journal-title":"BMJ (Clinical Res ed)"},{"issue":"8","key":"4257_CR41","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/crj.13663","volume":"17","author":"LC Terpstra","year":"2023","unstructured":"Terpstra LC, van der Geest D, Bronsveld I, Heijerman H, Boersma WG. Treatment with inhaled antibiotics in bronchiectasis, side effects, and evaluation of the tolerance test; analysis from the BATTLE randomized controlled trial. Clin Respir J. 2023;17(8):748\u201353.","journal-title":"Clin Respir J"},{"issue":"5","key":"4257_CR42","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1378\/chest.130.5.1503","volume":"130","author":"D Bilton","year":"2006","unstructured":"Bilton D, Henig N, Morrissey B, Gotfried M. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest. 2006;130(5):1503\u201310.","journal-title":"Chest"},{"issue":"3 Suppl","key":"4257_CR43","doi-asserted-by":"publisher","first-page":"s114","DOI":"10.1378\/chest.120.3_suppl.114S","volume":"120","author":"LA Couch","year":"2001","unstructured":"Couch LA. Treatment With tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa. Chest. 2001;120(3 Suppl):s114\u20137.","journal-title":"Chest"},{"key":"4257_CR44","doi-asserted-by":"publisher","unstructured":"Loebinger MR, Polverino E, Chalmers JD, Tiddens H, Goossens H, Tunney M, Ringshausen FC, Hill AT, Pathan R, Angyalosi G et al. Efficacy and safety of TOBI Podhaler in Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study. Eur Respir J. 2021;57(1):2001451. https:\/\/doi.org\/10.1183\/13993003.01451-2020.","DOI":"10.1183\/13993003.01451-2020"},{"issue":"4","key":"4257_CR45","first-page":"299","volume":"90","author":"R Orriols","year":"2015","unstructured":"Orriols R, Hernando R, Ferrer A, Terradas S, Montoro B. Eradication Therapy against Pseudomonas aeruginosa in Non-Cystic Fibrosis Bronchiectasis. Respir Int Rev Thorac Dis. 2015;90(4):299\u2013305.","journal-title":"Respir Int Rev Thorac Dis"},{"issue":"7","key":"4257_CR46","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S0954-6111(99)90090-2","volume":"93","author":"R Orriols","year":"1999","unstructured":"Orriols R, Roig J, Ferrer J, Sampol G, Rosell A, Ferrer A, Vallano A. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respir Med. 1999;93(7):476\u201380.","journal-title":"Respir Med"},{"issue":"1","key":"4257_CR47","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jcf.2022.08.007","volume":"22","author":"IG Casaredi","year":"2023","unstructured":"Casaredi IG, Shaw M, Waters V, Seeto R, Blanchard AC, Ratjen F. Impact of antibiotic eradication therapy of Pseudomonas aeruginosa on long term lung function in cystic fibrosis. J Cyst fibrosis: official J Eur Cyst Fibros Soc. 2023;22(1):98\u2013102.","journal-title":"J Cyst fibrosis: official J Eur Cyst Fibros Soc"},{"issue":"3","key":"4257_CR48","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1513\/AnnalsATS.201209-082OC","volume":"10","author":"RD VanDyke","year":"2013","unstructured":"VanDyke RD, McPhail GL, Huang B, Fenchel MC, Amin RS, Carle AC, Chini BA, Seid M. Inhaled tobramycin effectively reduces FEV1 decline in cystic fibrosis. An instrumental variables analysis. Annals Am Thorac Soc. 2013;10(3):205\u201312.","journal-title":"Annals Am Thorac Soc"},{"issue":"12","key":"4257_CR49","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1164\/rccm.201609-1954OC","volume":"195","author":"KB Hisert","year":"2017","unstructured":"Hisert KB, Heltshe SL, Pope C, Jorth P, Wu X, Edwards RM, Radey M, Accurso FJ, Wolter DJ, Cooke G, et al. Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections. Am J Respir Crit Care Med. 2017;195(12):1617\u201328.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"4257_CR50","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.arbres.2018.07.002","volume":"55","author":"M Martinez-Garcia","year":"2019","unstructured":"Martinez-Garcia M, Athanazio R, Gramblicka G, Corso M, Cavalcanti Lundgren F, Fernandes de Figueiredo M, Arancibia F, Rached S, Gir\u00f3n R, M\u00e1iz Carro L, et al. Prognostic Value of Frequent Exacerbations in Bronchiectasis: The Relationship With Disease Severity. Arch Bronconeumol. 2019;55(2):81\u20137.","journal-title":"Arch Bronconeumol"},{"key":"4257_CR51","doi-asserted-by":"publisher","unstructured":"Sibila O, Laserna E, Shoemark A, Perea L, Bilton D, Crichton ML, De Soyza A, Boersma WG, Altenburg J, Chalmers JD. Heterogeneity of treatment response in bronchiectasis clinical trials. Eur Respir J. 2022;59(5):2100777. https:\/\/doi.org\/10.1183\/13993003.00777-2021.","DOI":"10.1183\/13993003.00777-2021"},{"key":"4257_CR52","doi-asserted-by":"publisher","unstructured":"Crichton ML, Aliberti S, Chalmers JD. A systematic review of pharmacotherapeutic clinical trial end-points for bronchiectasis in adults. Eur respiratory review: official J Eur Respiratory Soc. 2019;28(151):180108. https:\/\/doi.org\/10.1183\/16000617.0108-2018.","DOI":"10.1183\/16000617.0108-2018"},{"key":"4257_CR53","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.rmed.2018.10.031","volume":"145","author":"D Radovanovic","year":"2018","unstructured":"Radovanovic D, Santus P, Blasi F, Sotgiu G, D\u2019Arcangelo F, Simonetta E, Contarini M, Franceschi E, Goeminne PC, Chalmers JD, et al. A comprehensive approach to lung function in bronchiectasis. Respir Med. 2018;145:120\u20139.","journal-title":"Respir Med"},{"issue":"9","key":"4257_CR54","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1513\/AnnalsATS.202006-584OC","volume":"19","author":"K O\u2019Neill","year":"2022","unstructured":"O\u2019Neill K, Lakshmipathy GR, Neely C, Cosgrove D, Ferguson K, McLeese R, Hill AT, Loebinger MR, Carroll M, Chalmers JD, et al. Multiple-Breath Washout Outcome Measures in Adults with Bronchiectasis. Annals Am Thorac Soc. 2022;19(9):1489\u201397.","journal-title":"Annals Am Thorac Soc"},{"key":"4257_CR55","doi-asserted-by":"publisher","first-page":"107660","DOI":"10.1016\/j.rmed.2024.107660","volume":"228","author":"TR Aksamit","year":"2024","unstructured":"Aksamit TR, Lapinel NC, Choate R, Feliciano J, Winthrop KL, Schmid A, Wu J, Fucile S, Metersky ML. Association between bronchiectasis exacerbations and longitudinal changes in FEV(1) in patients from the US bronchiectasis and NTM research registry. Respir Med. 2024;228:107660.","journal-title":"Respir Med"},{"issue":"1","key":"4257_CR56","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.molimm.2012.09.011","volume":"55","author":"JD Chalmers","year":"2013","unstructured":"Chalmers JD, Hill AT. Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. Mol Immunol. 2013;55(1):27\u201334.","journal-title":"Mol Immunol"},{"issue":"11","key":"4257_CR57","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1164\/rccm.201711-2202OC","volume":"197","author":"JD Chalmers","year":"2018","unstructured":"Chalmers JD, Aliberti S, Filonenko A, Shteinberg M, Goeminne PC, Hill AT, Fardon TC, Obradovic D, Gerlinger C, Sotgiu G, et al. Characterization of the Frequent Exacerbator Phenotype in Bronchiectasis. Am J Respir Crit Care Med. 2018;197(11):1410\u201320.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"4257_CR58","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/j.chest.2023.06.040","volume":"164","author":"JM Roberts","year":"2023","unstructured":"Roberts JM, Goyal V, Kularatna S, Chang AB, Kapur N, Chalmers JD, Goeminne PC, Hernandez F, Marchant JM, McPhail SM. The Economic Burden of Bronchiectasis: A Systematic Review. Chest. 2023;164(6):1396\u2013421.","journal-title":"Chest"},{"issue":"1","key":"4257_CR59","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12890-019-0818-6","volume":"19","author":"PC Goeminne","year":"2019","unstructured":"Goeminne PC, Hernandez F, Diel R, Filonenko A, Hughes R, Juelich F, Solomon GM, Upton A, Wichmann K, Xu W, et al. The economic burden of bronchiectasis - known and unknown: a systematic review. BMC Pulm Med. 2019;19(1):54.","journal-title":"BMC Pulm Med"},{"issue":"9","key":"4257_CR60","doi-asserted-by":"publisher","first-page":"967","DOI":"10.18553\/jmcp.2024.30.9.967","volume":"30","author":"J Tkacz","year":"2024","unstructured":"Tkacz J, Lewing B, Feliciano J, Mohanty M, Lauterio M, Fucile S, Barker A. Real-world treatment patterns, health care resource utilization, and costs in a US Medicare population with bronchiectasis. J managed care specialty Pharm. 2024;30(9):967\u201377.","journal-title":"J managed care specialty Pharm"},{"issue":"4","key":"4257_CR61","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1177\/1479972316643698","volume":"13","author":"D de la Rosa","year":"2016","unstructured":"de la Rosa D, Mart\u00ednez-Garcia MA, Olveira C, Gir\u00f3n R, M\u00e1iz L, Prados C. Annual direct medical costs of bronchiectasis treatment: Impact of severity, exacerbations, chronic bronchial colonization and chronic obstructive pulmonary disease coexistence. Chronic Resp Dis. 2016;13(4):361\u201371.","journal-title":"Chronic Resp Dis"},{"key":"4257_CR62","doi-asserted-by":"publisher","unstructured":"Ronco R, Franco G, Monzio Compagnoni M, Aliberti S, Luppi F, Corrao G, Faverio P. Healthcare costs and resource utilisation in bronchiectasis, asthma and COPD. ERJ open Res. 2023;9(4):00158\u20132023. https:\/\/doi.org\/10.1183\/23120541.00158-2023.","DOI":"10.1183\/23120541.00158-2023"},{"key":"4257_CR63","doi-asserted-by":"publisher","unstructured":"Chalmers JD, Haworth CS, Flume P, Long MB, Burgel PR, Dimakou K, Blasi F, Herrero-Cortina B, Dhar R, Chotirmall SH et al. European Respiratory Society clinical practice guideline for the management of adult bronchiectasis. Eur Respir J. 2025;66(6):2501126. https:\/\/doi.org\/10.1183\/13993003.01126-2025.","DOI":"10.1183\/13993003.01126-2025"},{"issue":"Suppl 1","key":"4257_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/thoraxjnl-2018-212463","volume":"74","author":"AT Hill","year":"2019","unstructured":"Hill AT, Sullivan AL, Chalmers JD, De Soyza A, Elborn SJ, Floto AR, Grillo L, Gruffydd-Jones K, Harvey A, Haworth CS, et al. British Thoracic Society Guideline for bronchiectasis in adults. Thorax. 2019;74(Suppl 1):1\u201369.","journal-title":"Thorax"},{"issue":"8","key":"4257_CR65","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1164\/rccm.201312-2208OC","volume":"189","author":"CS Haworth","year":"2014","unstructured":"Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 2014;189(8):975\u201382.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"4257_CR66","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S2213-2600(14)70165-1","volume":"2","author":"AF Barker","year":"2014","unstructured":"Barker AF, O\u2019Donnell AE, Flume P, Thompson PJ, Ruzi JD, de Gracia J, Boersma WG, De Soyza A, Shao L, Zhang J, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respiratory Med. 2014;2(9):738\u201349.","journal-title":"Lancet Respiratory Med"},{"issue":"2","key":"4257_CR67","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1055\/s-0035-1547346","volume":"36","author":"GT Tay","year":"2015","unstructured":"Tay GT, Reid DW, Bell SC. Inhaled antibiotics in Cystic Fibrosis (CF) and non-CF bronchiectasis. Semin Respir Crit Care Med. 2015;36(2):267\u201386.","journal-title":"Semin Respir Crit Care Med"},{"issue":"2","key":"4257_CR68","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1093\/jac\/dkac412","volume":"78","author":"JM Schultheis","year":"2023","unstructured":"Schultheis JM, Durham ME, Kram SJ, Kuhrt M, Gilstrap DL, Parish A, Green CL, Kram BL. Incidence and associated risk factors for systemic drug levels with inhaled aminoglycoside therapy. J Antimicrob Chemother. 2023;78(2):450\u20136.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"4257_CR69","doi-asserted-by":"publisher","first-page":"464","DOI":"10.5414\/CNP66464","volume":"66","author":"MJ Izquierdo","year":"2006","unstructured":"Izquierdo MJ, Gomez-Alamillo C, Ortiz F, Calabia ER, Ruiz JC, de Francisco AL, Arias M. Acute renal failure associated with use of inhaled tobramycin for treatment of chronic airway colonization with Pseudomonas aeruginosa. Clin Nephrol. 2006;66(6):464\u20137.","journal-title":"Clin Nephrol"},{"key":"4257_CR70","doi-asserted-by":"publisher","unstructured":"Miller T, Pastuch C, Garavaglia L, Gannon K, Parravani A: Unknown Renal Impairment: A Rare Case of Inhaled Tobramycin Induced Acute Kidney Injury in a Cystic Fibrosis Patient., Antibiotics. (Basel, Switzerland). 2021;10(4):424. https:\/\/doi.org\/10.3390\/antibiotics10040424.","DOI":"10.3390\/antibiotics10040424"},{"key":"4257_CR71","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2147\/COPD.S150250","volume":"13","author":"YH Gao","year":"2018","unstructured":"Gao YH, Guan WJ, Zhu YN, Chen RC, Zhang GJ. Antibiotic-resistant Pseudomonas aeruginosa infection in patients with bronchiectasis: prevalence, risk factors and prognostic implications. Int J Chronic Obstr Pulm Dis. 2018;13:237\u201346.","journal-title":"Int J Chronic Obstr Pulm Dis"},{"issue":"5","key":"4257_CR72","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1080\/17476348.2021.1906225","volume":"15","author":"C Vidaillac","year":"2021","unstructured":"Vidaillac C, Chotirmall SH. Pseudomonas aeruginosa in bronchiectasis: infection, inflammation, and therapies. Expert Rev Respir Med. 2021;15(5):649\u201362.","journal-title":"Expert Rev Respir Med"},{"issue":"5","key":"4257_CR73","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1164\/rccm.201309-1575OC","volume":"189","author":"JD Chalmers","year":"2014","unstructured":"Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, Poppelwell L, Salih W, Pesci A, Dupont LJ, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. 2014;189(5):576\u201385.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"4257_CR74","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1183\/09031936.00026313","volume":"43","author":"M Mart\u00ednez-Garc\u00eda","year":"2014","unstructured":"Mart\u00ednez-Garc\u00eda M, de Gracia J, Vendrell Relat M, Gir\u00f3n RM, M\u00e1iz Carro L, de la Rosa Carrillo D, Olveira C. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J. 2014;43(5):1357\u201367.","journal-title":"Eur Respir J"},{"issue":"4","key":"4257_CR75","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1183\/09031936.00003709","volume":"34","author":"MR Loebinger","year":"2009","unstructured":"Loebinger MR, Wells AU, Hansell DM, Chinyanganya N, Devaraj A, Meister M, Wilson R. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J. 2009;34(4):843\u20139.","journal-title":"Eur Respir J"},{"issue":"7","key":"4257_CR76","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.rmed.2007.02.002","volume":"101","author":"ZP Onen","year":"2007","unstructured":"Onen ZP, Gulbay BE, Sen E, Yildiz OA, Saryal S, Acican T, Karabiyikoglu G. Analysis of the factors related to mortality in patients with bronchiectasis. Respir Med. 2007;101(7):1390\u20137.","journal-title":"Respir Med"},{"issue":"1","key":"4257_CR77","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/thoraxjnl-2014-205918","volume":"70","author":"AL Quittner","year":"2015","unstructured":"Quittner AL, O\u2019Donnell AE, Salathe MA, Lewis SA, Li X, Montgomery AB, O\u2019Riordan TG, Barker AF. Quality of Life Questionnaire-Bronchiectasis: final psychometric analyses and determination of minimal important difference scores. Thorax. 2015;70(1):12\u201320.","journal-title":"Thorax"},{"issue":"8","key":"4257_CR78","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1136\/thoraxjnl-2015-207315","volume":"71","author":"A Spinou","year":"2016","unstructured":"Spinou A, Fragkos KC, Lee KK, Elston C, Siegert RJ, Loebinger MR, Wilson R, Garrod R, Birring SS. The validity of health-related quality of life questionnaires in bronchiectasis: a systematic review and meta-analysis. Thorax. 2016;71(8):683\u201394.","journal-title":"Thorax"},{"key":"4257_CR79","doi-asserted-by":"publisher","unstructured":"Aksamit T, De Soyza A, Bandel TJ, Criollo M, Elborn JS, Operschall E, Polverino E, Roth K, Winthrop KL, Wilson R. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur Respir J. 2018;51(1):1702053. https:\/\/doi.org\/10.1183\/13993003.02053-2017.","DOI":"10.1183\/13993003.02053-2017"},{"key":"4257_CR80","doi-asserted-by":"publisher","first-page":"1405376","DOI":"10.3389\/fimmu.2024.1405376","volume":"15","author":"R Nickerson","year":"2024","unstructured":"Nickerson R, Thornton CS, Johnston B, Lee AHY, Cheng Z. Pseudomonas aeruginosa in chronic lung disease: untangling the dysregulated host immune response. Front Immunol. 2024;15:1405376.","journal-title":"Front Immunol"},{"key":"4257_CR81","doi-asserted-by":"publisher","unstructured":"Gao YH, Lu HW, Zheng HZ, Cao C, Chu DJ, Fan H, Fan XY, Gu HY, Guan WJ, Jie ZJ et al. A phase 4 multicentre, 2\u00d72 factorial randomised, double-blind, placebo-controlled trial to investigate the efficacy and safety of tobramycin inhalation solution for Pseudomonas aeruginosa eradication in bronchiectasis: ERASE. ERJ open Res. 2024;10(1):00938-2023. https:\/\/doi.org\/10.1183\/23120541.00938-2023.","DOI":"10.1183\/23120541.00938-2023"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-026-04257-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04257-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04257-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T02:02:43Z","timestamp":1780884163000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12890-026-04257-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4257"],"URL":"https:\/\/doi.org\/10.1186\/s12890-026-04257-4","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"264"}}